NEUROMETRIX, INC. (NASDAQ:NURO) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01 Changes in Registrant’s Certifying Accountant
Committee of the Board of Directors (the “Audit Committee”)
dismissed PricewaterhouseCoopers LLP (“PwC”) as the Company’s
independent registered public accounting firm and appointed Moody,
Famiglietti Andronico, LLP (“MFA”) as the Company’s new
independent registered public accounting firm.
fiscal years ended December 31, 2016 and 2015 contained no adverse
opinion or disclaimer of opinion and were not qualified or modified
as to audit scope or accounting principles, except that the reports
for both years contained a paragraph stating that there was
substantial doubt about the Company’s ability to continue as a
going concern.
subsequent period through April 4, 2017, there were no
disagreements with PwC on any matter of accounting principles or
practices, financial statement disclosure, or auditing scope or
procedure, which disagreements, if not resolved to the satisfaction
of PwC, would have caused PwC to make reference to the subject
matter of the disagreements in their reports. During the fiscal
years ended December 31, 2016 and 2015 and the subsequent period
through April 4, 2017, there have been no reportable events (as
defined in Regulation S-K 304(a)(1)(v)).
subsequent interim period through April 4, 2017, the date of PwC’s
dismissal, neither the Company, nor anyone on its behalf, consulted
MFA regarding either (i) the application of accounting principles
to a specific transaction, either completed or proposed; or the
type of audit opinion that might be rendered on the registrant’s
financial statements, and no written report or oral advice was
provided to the Company that was an important factor considered by
the Company in reaching its decision as to an accounting, auditing,
or financial reporting issue; or (ii) any matter that was either
the subject of a disagreement (as defined in paragraph
304(a)(1)(iv) of Regulation S-K and the related instructions) or a
reportable event (as described in paragraph 304(a)(1)(v) of
Regulation S-K).
provided PwC with a copy of the statements set forth above prior to
the time this Current Report on Form 8-K was filed with the
Securities and Exchange Commission (“SEC”). The Company requested
that PwC furnish the Company with a letter addressed to the SEC
stating whether PwC agrees with the above statements. PwC has
furnished the requested letter, and it is attached as an exhibit to
this report.
|
|
|
|
|
Exhibit
|
|
|
|
Number
|
|
Exhibit Description
|
|
16.1
|
|
Letter from PricewaterhouseCoopers LLP dated April 6,
2017. |
About NEUROMETRIX, INC. (NASDAQ:NURO)
NeuroMetrix, Inc. (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases and sleep disorders. The Company operates through the sale of medical equipment and consumables segment. Its products are sold in the United States and selected overseas markets. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The Company’s products consist of a medical device used in conjunction with a consumable electrode or biosensor. Its products include Quell, which is a wearable device for relief of chronic intractable pain; SENSUS, which is a prescription neuro-stimulation device; DPNCheck, which is a nerve conduction test that is used to evaluate systemic neuropathies, and ADVANCE System, which is a platform for the performance of nerve conduction studies. NEUROMETRIX, INC. (NASDAQ:NURO) Recent Trading Information
NEUROMETRIX, INC. (NASDAQ:NURO) closed its last trading session down -0.004 at 0.615 with 52,861 shares trading hands.